Halda Therapeutics secures $126 million financing to advance RIPTAC cancer therapies
- Halda Therapeutics raised $126 million in a Series B extension, bringing total funding to $202 million.
- Funding will advance two RIPTAC candidates into clinical trials for metastatic prostate and breast cancer.
- Lead candidate HLD-0915 to start Phase 1 trial for metastatic, castration-resistant prostate cancer in H1 2025.
- Financing will also support team expansion and development of additional RIPTAC-based products.
Read more
Kiromic BioPharma provides update on part 1 of the Deltacel-01 trial
- Kiromic BioPharma reports interim results for Part 1 of its Deltacel-01 Phase 1 clinical trial.
- The trial evaluates Deltacel (KB-GDT-01) in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).
- Progression-Free Survival (PFS) for five patients ranged from 2 to 8 months, averaging 4.8 months.
- No dose limiting toxicities (DLTs) reported; one patient withdrew due to an unrelated adverse event.
- The last patient in Part 1 started treatment on August 6th; early safety outcomes expected in September and efficacy results in October.
- Part 2 of the Deltacel-01 study is set to begin in September.
Read more
